Arcellx (NASDAQ:ACLX) Stock Price Up 5.1% After Analyst Upgrade
Arcellx, Inc. (NASDAQ:ACLX – Get Free Report)’s share price rose 5.1% on Wednesday after UBS Group raised their price target on the stock from $106.00 to $114.00. UBS Group currently has a buy rating ...
kalkinemedia1d
Why Is Arcellx Gaining Traction After UBS Group’s Latest Move?
Highlights:,Arcellx, Inc.,(NASDAQ:ACLX),experienced a 5.1% increase in its stock price.,UBS Group raised its price target for ...
HC Wainwright Reiterates Buy Rating for Arcellx (NASDAQ:ACLX)
Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to ...
Arcellx Inc (ACLX) Gets a Buy from Truist Financial
In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Arcellx Inc (ACLX – Research Report). The ...
marketinference3d
Arcellx Reports Positive Data for Anitocabtagene Autoleucel in RRMM
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company focusing on developing innovative immunotherapies for patients with ...
In-Depth Examination Of 14 Analyst Recommendations For Arcellx
Analysts have recently evaluated Arcellx and provided 12-month price targets. The average target is $107.71, accompanied by a ...
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel ...
Arcellx Inc (ACLX) Receives a Buy from Scotiabank
Scotiabank analyst George Farmer maintained a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $133.00. The ...
Seeking Alpha14d
Janus Henderson Global Life Sciences Fund Q3 2024 Commentary
Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss ...